253 related articles for article (PubMed ID: 34712131)
1. Evaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis.
Roach KM; Castells E; Dixon K; Mason S; Elliott G; Marshall H; Poblocka MA; Macip S; Richardson M; Khalfaoui L; Bradding P
Front Pharmacol; 2021; 12():679388. PubMed ID: 34712131
[No Abstract] [Full Text] [Related]
2. A model of human lung fibrogenesis for the assessment of anti-fibrotic strategies in idiopathic pulmonary fibrosis.
Roach KM; Sutcliffe A; Matthews L; Elliott G; Newby C; Amrani Y; Bradding P
Sci Rep; 2018 Jan; 8(1):342. PubMed ID: 29321510
[TBL] [Abstract][Full Text] [Related]
3. Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis.
Lehtonen ST; Veijola A; Karvonen H; Lappi-Blanco E; Sormunen R; Korpela S; Zagai U; Sköld MC; Kaarteenaho R
Respir Res; 2016 Feb; 17():14. PubMed ID: 26846335
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of Nintedanib and Pirfenidone on lung alveolar epithelial cell function in ex vivo murine and human lung tissue cultures of pulmonary fibrosis.
Lehmann M; Buhl L; Alsafadi HN; Klee S; Hermann S; Mutze K; Ota C; Lindner M; Behr J; Hilgendorff A; Wagner DE; Königshoff M
Respir Res; 2018 Sep; 19(1):175. PubMed ID: 30219058
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP; Ponnuswamy A; Dutta P; Abdelaziz A; Kamil H
BMC Pulm Med; 2021 Dec; 21(1):411. PubMed ID: 34895203
[TBL] [Abstract][Full Text] [Related]
6. Combination of esomeprazole and pirfenidone enhances antifibrotic efficacy in vitro and in a mouse model of TGFβ-induced lung fibrosis.
Ebrahimpour A; Ahir M; Wang M; Jegga AG; Bonnen MD; Eissa NT; Montesi SB; Raghu G; Ghebre YT
Sci Rep; 2022 Nov; 12(1):20668. PubMed ID: 36450789
[TBL] [Abstract][Full Text] [Related]
7. Fibroblast-matrix interplay: Nintedanib and pirfenidone modulate the effect of IPF fibroblast-conditioned matrix on normal fibroblast phenotype.
Epstein Shochet G; Wollin L; Shitrit D
Respirology; 2018 Aug; 23(8):756-763. PubMed ID: 29532550
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects.
Overed-Sayer C; Miranda E; Dunmore R; Liarte Marin E; Beloki L; Rassl D; Parfrey H; Carruthers A; Chahboub A; Koch S; Güler-Gane G; Kuziora M; Lewis A; Murray L; May R; Clarke D
Thorax; 2020 Sep; 75(9):754-763. PubMed ID: 32709610
[TBL] [Abstract][Full Text] [Related]
9. Increased constitutive αSMA and Smad2/3 expression in idiopathic pulmonary fibrosis myofibroblasts is KCa3.1-dependent.
Roach KM; Wulff H; Feghali-Bostwick C; Amrani Y; Bradding P
Respir Res; 2014 Dec; 15(1):155. PubMed ID: 25476248
[TBL] [Abstract][Full Text] [Related]
10. Absence of early metabolic response assessed by 18F-FDG PET/CT after initiation of antifibrotic drugs in IPF patients.
Bondue B; Castiaux A; Van Simaeys G; Mathey C; Sherer F; Egrise D; Lacroix S; Huaux F; Doumont G; Goldman S
Respir Res; 2019 Jan; 20(1):10. PubMed ID: 30646908
[TBL] [Abstract][Full Text] [Related]
11. Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib.
Zhang Y; Jones KD; Achtar-Zadeh N; Green G; Kukreja J; Xu B; Wolters PJ
Histopathology; 2019 Jan; 74(2):341-349. PubMed ID: 30152895
[TBL] [Abstract][Full Text] [Related]
12. Surfactant protein A as a biomarker of outcomes of anti-fibrotic drug therapy in patients with idiopathic pulmonary fibrosis.
Yoshikawa T; Otsuka M; Chiba H; Ikeda K; Mori Y; Umeda Y; Nishikiori H; Kuronuma K; Takahashi H
BMC Pulm Med; 2020 Jan; 20(1):27. PubMed ID: 32005219
[TBL] [Abstract][Full Text] [Related]
13. A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Knüppel L; Ishikawa Y; Aichler M; Heinzelmann K; Hatz R; Behr J; Walch A; Bächinger HP; Eickelberg O; Staab-Weijnitz CA
Am J Respir Cell Mol Biol; 2017 Jul; 57(1):77-90. PubMed ID: 28257580
[TBL] [Abstract][Full Text] [Related]
14. Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis.
Ikeda S; Sekine A; Baba T; Katano T; Tabata E; Shintani R; Sadoyama S; Yamakawa H; Oda T; Okuda R; Kitamura H; Iwasawa T; Takemura T; Ogura T
BMC Pulm Med; 2019 Apr; 19(1):78. PubMed ID: 30975118
[TBL] [Abstract][Full Text] [Related]
15. Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis.
Inomata M; Nishioka Y; Azuma A
Core Evid; 2015; 10():89-98. PubMed ID: 26346347
[TBL] [Abstract][Full Text] [Related]
16. Nintedanib for the treatment of idiopathic pulmonary fibrosis.
Varone F; Sgalla G; Iovene B; Bruni T; Richeldi L
Expert Opin Pharmacother; 2018 Feb; 19(2):167-175. PubMed ID: 29327616
[TBL] [Abstract][Full Text] [Related]
17. South-West of England's Experience of the Safety and Tolerability Pirfenidone and Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Mulholland S; Al Jbour K; Steer H; Gutsche M; Foley N; Srivastava R; Sharp C; Adamali HI
Front Pharmacol; 2018; 9():1480. PubMed ID: 30618768
[No Abstract] [Full Text] [Related]
18. Human lung myofibroblast TGFβ1-dependent Smad2/3 signalling is Ca(2+)-dependent and regulated by KCa3.1 K(+) channels.
Roach KM; Feghali-Bostwick C; Wulff H; Amrani Y; Bradding P
Fibrogenesis Tissue Repair; 2015; 8():5. PubMed ID: 25829947
[TBL] [Abstract][Full Text] [Related]
19. Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF).
Saito S; Alkhatib A; Kolls JK; Kondoh Y; Lasky JA
J Thorac Dis; 2019 Sep; 11(Suppl 14):S1740-S1754. PubMed ID: 31632751
[TBL] [Abstract][Full Text] [Related]
20. Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone.
Lacedonia D; Correale M; Tricarico L; Scioscia G; Stornelli SR; Simone F; Casparrini M; Brunetti ND; Foschino Barbaro MP
Intern Emerg Med; 2022 Apr; 17(3):815-822. PubMed ID: 34787802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
